Atorvastatin calcium and Ocular hyperaemia - a phase IV clinical study of FDA data

Summary:

Ocular hyperaemia is reported as a side effect among people who take Atorvastatin calcium (atorvastatin calcium), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Oxervate, and have Neurotrophic keratopathy.

The phase IV clinical study analyzes which people have Ocular hyperaemia when taking Atorvastatin calcium. It is created by eHealthMe based on reports of 72,753 people who have side effects when taking Atorvastatin calcium from the FDA, and is updated regularly.

What is Atorvastatin calcium?

Atorvastatin calcium has active ingredients of atorvastatin calcium. It is often used in high blood cholesterol. eHealthMe is studying from 77,309 Atorvastatin calcium users. Check the latest studies of Atorvastatin calcium.

What is Ocular hyperaemia?

Ocular hyperaemia (an abnormally large amount of blood in eye) is found to be associated with 1,357 drugs and 1,499 conditions by eHealthMe. Check the latest studies of Ocular hyperaemia.

On Jul, 08, 2026

72,753 people reported to have side effects when taking Atorvastatin calcium.
Among them, 170 people (0.23%) have Ocular hyperaemia.

Could Atorvastatin calcium cause Ocular hyperaemia?

Among these 170 people:

How long have people been on Atorvastatin calcium when they have Ocular hyperaemia? *

Click here to view more results

What is the gender of people who have Ocular hyperaemia when taking Atorvastatin calcium? *

Click here to view

What is the age of people who have Ocular hyperaemia when taking Atorvastatin calcium? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Atorvastatin calcium and have Ocular hyperaemia?

- Check whether Ocular hyperaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Atorvastatin calcium:

Atorvastatin calcium (77,309 reports)

Ocular hyperaemia treatments and more:

Ocular hyperaemia (47,107 reports)

How severe was Ocular hyperaemia and when was it recovered:

Ocular hyperaemia in Atorvastatin calcium

Expand to all the drugs that have ingredients of atorvastatin calcium:

Ocular hyperaemia and drugs with ingredients of atorvastatin calcium (1,064 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Atorvastatin calcium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ocular hyperaemia:

Ocular hyperaemia (1,357 drugs)

Browse all the conditions that are associated with Ocular hyperaemia:

Ocular hyperaemia (1,499 conditions)

Related publications that referenced our studies

Proti? D, Balti? S, Stupar N, Pavlov-Dolijanovi? S, Mugo?a S, Todorovi? Z, "A case of myositis with immunological background associated with statin use", Open Medicine, 2014 Oct .
Goldie MP, "Atorvastatin: a new treatment for periodontal disease?", , 2012 Jan .
Proti? D, Balti? S, Stupar N, Pavlov-Dolijanovi? S, Mugo?a S, Todorovi? Z, "A case of myositis with immunological background associated with statin use", Open Medicine, 2014 Oct .
Goldie MP, "Atorvastatin: a new treatment for periodontal disease?", , 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on atorvastatin calcium (the active ingredients of Atorvastatin calcium) and Atorvastatin calcium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.